MENU
+Compare
MRSN
Stock ticker: NASDAQ
AS OF
Jul 3 closing price
Price
$0.29
Change
+$0.01 (+3.57%)
Capitalization
36.08M

MRSN Mersana Therapeutics Forecast, Technical & Fundamental Analysis

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs... Show more

Industry: #Biotechnology
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for MRSN with price predictions
Jul 03, 2025

Momentum Indicator for MRSN turns negative, indicating new downward trend

MRSN saw its Momentum Indicator move below the 0 level on June 18, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In of the 89 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for MRSN turned negative on June 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

MRSN moved below its 50-day moving average on June 23, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MRSN crossed bearishly below the 50-day moving average on June 25, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRSN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MRSN's RSI Indicator exited the oversold zone, of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRSN advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

MRSN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 138 cases where MRSN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (61.728) is normal, around the industry mean (16.666). P/E Ratio (0.000) is within average values for comparable stocks, (58.763). MRSN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.315). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (1.050) is also within normal values, averaging (269.614).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MRSN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRSN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

MRSN is expected to report earnings to fall 17.16% to -15 cents per share on August 06

Mersana Therapeutics MRSN Stock Earnings Reports
Q2'25
Est.
$-0.16
Q1'25
Est.
$-0.19
Q4'24
Beat
by $0.04
Q3'24
Missed
by $0.18
Q2'24
Missed
by $0.03
The last earnings report on May 15 showed earnings per share of -18 cents, meeting the estimate of -18 cents. With 1.86M shares outstanding, the current market capitalization sits at 36.08M.
A.I. Advisor
published General Information

General Information

a developer of antibody drug conjugates to improve patient outcomes in multiple oncology indications

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
840 Memorial Drive
Phone
+1 617 498-0020
Employees
123
Web
https://www.mersana.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ATUS2.220.13
+6.22%
Altice USA
PANW201.824.85
+2.46%
Palo Alto Networks Inc
OBT27.420.27
+0.99%
Orange County Bancorp Inc
HR15.920.11
+0.70%
Healthcare Realty Trust
CLNN3.90-0.05
-1.27%
Clene Inc.

MRSN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MRSN has been loosely correlated with IGMS. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if MRSN jumps, then IGMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRSN
1D Price
Change %
MRSN100%
+3.50%
IGMS - MRSN
55%
Loosely correlated
+3.03%
CRNX - MRSN
48%
Loosely correlated
+1.22%
DYN - MRSN
47%
Loosely correlated
-2.01%
DNLI - MRSN
42%
Loosely correlated
-1.41%
RGNX - MRSN
42%
Loosely correlated
+1.39%
More